CASE REPORT

Case Report: Application of whole exome sequencing for accurate diagnosis of rare syndromes of mineralocorticoid excess [version 2; peer review: 2 approved]

Ranjit Narayanan¹, Shamsudheen Karuthedath Vellarikkaal²,³, Rijith Jayarajan³, Ankit Verma³, Vishal Dixit³, Vinod Scaria²,⁴, Sridhar Sivasubbu²,³

¹Department of Nephrology, KMCT Medical College Hospital, Kerala, India
²Academy of Scientific and Innovative Research (AcSIR), CSIR-IGIB South Campus, Delhi, India
³Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, India
⁴GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, India

Abstract
Syndromes of mineralocorticoid excess (SME) are closely related clinical manifestations occurring within a specific set of diseases. Overlapping clinical manifestations of such syndromes often create a dilemma in accurate diagnosis, which is crucial for disease surveillance and management especially in rare genetic disorders. Here we demonstrate the use of whole exome sequencing (WES) for accurate diagnosis of rare SME and report that p.R337C variation in the HSD11B2 gene causes progressive apparent mineralocorticoid excess (AME) syndrome in a South Indian family of Mappila origin.

Keywords
whole exome sequencing, mineralocorticoid excess
Corresponding authors: Ranjit Narayanan (ranjitnarayanan@gmail.com), Vinod Scaria (vinods@igib.in), Sridhar Sivasubbu (sridhar@igib.in)

Author roles: Narayanan R: Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; Karuthedath Vellarikkal S: Formal Analysis, Methodology, Validation, Writing – Original Draft Preparation; Jayarajan R: Formal Analysis, Methodology, Validation; Verma A: Methodology, Validation, Writing – Review & Editing; Dixit V: Methodology; Scaria V: Conceptualization, Funding Acquisition, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; Sivasubbu S: Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Authors acknowledge funding from the Council of Scientific and Industrial Research (CSIR), India through Grant No. BSC0212 (Wellness genomics project) granted to SS and VS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Narayanan R et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


First published: 06 Jul 2016, 5:1592 (https://doi.org/10.12688/f1000research.8779.1)
Abbreviations
SME: Syndromes of mineralocorticoid excess; AME: Apparent Mineralocorticoid Excess; CAH: 17α-hydroxylase: Congenital adrenal hyperplasia due to 17α-hydroxylase deficiency; CAH: 11β-hydroxylase deficiency; Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency; CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1; CYP11B1: cytochrome P450, family 11, subfamily B, polypeptide 1; HSD11B2: hydroxysteroid (11β) dehydrogenase 2, ENaC: the epithelial sodium channel subunit genes, WNK1: WNK lysine deficient protein kinase 1, WNK4: WNK lysine deficient protein kinase 1; KLHL3: kelch-like family member 3, CUL3: cullin 3; SPAK: type III secretion system chaperone; MCR/NR3C2: Nuclear Receptor Subfamily 3, Group C, Member 2; WES: Whole exome sequencing.

Introduction
Syndromes of mineralocorticoid excess (SME) are a group of syndromes characterized by an abnormal activation of the amiloride-sensitive sodium channels in the distal tubules of the kidney resulting in an abnormal salt balance. The symptoms are characteristically an abnormality in salt balance (due to an over activation of the channels mediated through the mineralocorticoid receptor), water retention, hypokalemia, low renin levels and hypertension1-4. The syndrome of apparent mineralocorticoid excess is a rare autosomal recessive form of severe juvenile hypertension which occurs due to mutations in the HSD11B2 gene5 (OMIM #614232). HSD11B2 is responsible for oxidising glucocorticoid cortisol into inactive cortisone, which does not bind to the mineralocorticoid receptor. Since cortisol binds as avidly as aldosterone to the mineralocorticoid receptor, and the usual plasma cortisol concentration is approximately 100-fold higher than aldosterone, the deficiency of 11β-HSD2 enzyme leads to the persistence of cortisol. This in turn results in marked elevation in net mineralocorticoid activity5. Based on the clinical presentation, differential diagnosis would include Liddle syndrome, Geller syndrome, Gordon syndrome, Apparent Mineralocorticoid Excess (AME) and other milder variants such as CAH: 17α-hydroxylase and CAH: 11β-hydroxylase deficiency. Mutations in various genes including CYP17A1, CYP11B1, HSD11B2, ENaC, WNK1, WNK4, KLHL3, CUL3, SPAK and MCR/NR3C2 may result in clinical features that resemble SME1-5. Due to the large diversity and overlapping clinical features, accurate diagnosis is highly reliant on genetic characterization. The need to screen a large number of variants and genes that could cause disease, using conventional approaches such as capillary sequencing is tedious, time consuming and often expensive. Whole exome sequencing (WES) has emerged as an alternative strategy in such clinical settings6-8.

Case history
A 30-year-old male, presented to clinic with accelerated hypertension and palpitations. Clinical workup revealed hypokalemia and renal dysfunction. He had a history of hypokalemic paralysis at the age of 15 and was found to be hypertensive at the age of 18. He now had a BP of 170/100 mmHg with no clinical signs of volume overload. There was 1+ albuminuria without any active urinary sediment, while serum creatinine was 2.2 mg/dL and serum potassium was 3 meq/dL. Ultrasound imaging revealed normal sized kidneys with medullary nephrocalcinosis. Blood gas analysis showed a pH of 7.42 with bicarbonate of 24 meq/dL. His 2D echocardiography showed significant left ventricular hypertrophy (LVH). His plasma aldosterone (28 pg/ml) (normal: 30–355 pg/ml) and plasma renin activity (PRA) (0.14 ng/ml/hr) (normal: 1.9–6.0 ng/ml/hr) were low. He was started on spironolactone (50mg daily) in addition to amlodipine (10mg) and metoprolol (50 mg daily) with which his blood pressure came under control.

His younger brother, who was 28-year-old, had a similar presentation in the form of hypokalemic paralysis at 15 and accelerated hypertension at age 18. The patient’s blood tests from when he was 18 years old, showed serum creatinine levels of 0.7 mg/dL and potassium levels of 2.4 meq/L. Plasma aldosterone (6.5pg/ml) and plasma renin activity (PRA) (0.1 mg/ml/hr) were low on initial evaluation but there was no follow-up for the next few years. When called for evaluation now, his BP was 220/110 mmHg; serum creatinine was 2.0-mg/dL and serum potassium 3.0 meq/L. He did not have any albuminuria. Blood gas analysis showed a normal pH with bicarbonate of 25 mmol/L. He also had medullary nephrocalcinosis on abdominal imaging and significant LVH on 2D echocardiography. He remains extremely irregular with follow-up and still has uncontrolled BP.

The index patient is the eldest (30 years old) and the brother mentioned (28 years old) is the second of five siblings, the others being females aged 22, 18 and 14 years old (Figure-1A). The two older sisters have a history of hypertension and hypokalemia. The 18-year-old sister has serum creatinine levels of 1.5 mg/dL, with serum potassium levels of 3.2 meq/L. Plasma aldosterone (6.5pg/ml) and plasma renin activity (PRA) (0.1 mg/ml/hr) were low on initial evaluation but there was no follow-up for the next few years. When called for evaluation now, his BP was 220/110 mmHg; serum creatinine was 2.0-mg/dL and serum potassium 3.0 meq/L. He did not have any albuminuria. Blood gas analysis showed a normal pH with bicarbonate of 25 mmol/L. He also had medullary nephrocalcinosis on abdominal imaging and significant LVH on 2D echocardiography. He remains extremely irregular with follow-up and still has uncontrolled BP.

Whole exome sequencing, data analysis and validation
Whole blood was collected from the parents and the affected family members after obtaining written informed consent. DNA was extracted from blood and 50 ng of the high quality DNA of the index patient (30 years old) was used to prepare library and
Our family presented with features of mineralocorticoid excess, nephrocalcinosis, autosomal recessive inheritance pattern and varying degrees of renal dysfunction with low aldosterone and plasma renin activity (PRA). We used WES to characterize and diagnose this family with apparent mineralocorticoid excess and identified a mutation c.1009C>T (p.R337C) in *HSD11B2*. Human cell line studies have demonstrated that p.R337C mutation leads to the low activity of HSD11B2 due to reduced enzyme stability and causes low-renin hypertension thus resulting in AME. The p.R337 residue of 11-β-dehydrogenase isozyme 2 enzyme is a recognised mutation site and has been reported in Zoroastrians from India and Iran (compound heterozygous for p.R337H and Δp.Y338, age of onset from 8 months), in Persian (p.R337C, age of onset from 4 years) and in Japanese (p.R337H and Δp.Y338, age of onset from 2 years) populations. The age of onset for the disease manifestation due to p.R337C mutation has been previously described to be as early as 4 years. Unlike previous reports with this mutation where the age of onset has been early (8 months to 4 years), our family did not present with clinical symptoms in early childhood but exhibited or manifested the progressive AME phenotypes with increasing age (Figure 1A) with the older individuals having more severe clinical manifestations including renal impairment. Patients with identical homozygous mutations from different families have been described to have varying degrees of severity in clinical and

---

**Figure 1.** (A) Family pedigree marked with progressive phenotypes. (B) Secondary structure of HSD11B2 marked with major domains and the p.R337C amino acid position. (C) Capillary sequencing chromatogram representation of p.R337C variation in the family; arrow and asterisks marks depict the variation loci and affected individuals respectively.

---

exome capture using the Nextera Rapid Capture Expanded Exome kit. The sequencing was performed on Illumina HiSeq 2500 sequencer using v3 reagents (Illumina Inc, USA) to generate over 49.48 million paired end reads of 101bp. The variation calling, annotation and prioritisation were performed as previously described, which revealed the presence of homozygous C to T transition in the exon 5 (c.1009C>T) of the *HSD11B2* gene (Ensemble transcript ID: NM_000196) causing protein change of p.R337C (Figure-1B). The variant was found to be pathogenic in ClinVar and predicted to be deleterious using PROVEAN. The variant was further validated using Sanger sequencing of the amplicons, confirming the diagnosis (Figure-1C). Both the parents were heterozygous for the mutation.

**Discussion**

AME is a rare heterogeneous low renin retention SME disorder that manifests with severe juvenile hypertension, hypokalemic alkalosis, low birth weight, failure to thrive, poor growth, and in many cases nephrocalcinosis caused by homozygous and compound heterozygous mutations in the *HSD11B2* gene. The mutations in *HSD11B2* result in a high circulating level of cortisol, and further illegitimate activation of the mineralocorticoid receptor, outcompeting aldosterone and causing activation of the downstream pathways and a clinical presentation of AME symptoms.
biochemical features\(^\text{10}\). Early diagnosis and prompt institution of salt restriction and spironolactone in these patients could prevent secondary organ damage. Our report also serves to highlight the utility of WES as a tool for diagnosing rare genetic diseases even where biochemical characterization is unavailable.

**Patient consent**
Written informed consent for publication of these data were obtained from the patients.

**Data availability**
The raw whole exome sequence are available at the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra), accession number SRR3546815.

**Author contributions**
Clinical workup: RN; WES data generation, analysis, and validation: SKV, RJ, AV, VD; supervision and mentorship: VS and SS; All authors contributed important intellectual contents during manuscript drafting and accepts accountability for the overall work.

**Competing interests**
No competing interests were disclosed.

**Grant information**
Authors acknowledge funding from the Council of Scientific and Industrial Research (CSIR), India through Grant No. BSC0212 (Wellness genomics project) granted to SS and VS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Acknowledgement**
Authors acknowledge help and support from the GUaRDIAN Consortium. RN acknowledges Dr. Moumita Barua from the Dept. of Medicine, Toronto General Hospital, University of Toronto and Prof. Martin Russell Pollak from Beth Israel Deaconess Medical Center at Harvard Medical School for their input and help during initial workup.

**References**

Open Peer Review

Current Peer Review Status: ✅ ▶️

Version 2

Reviewer Report 06 October 2017

https://doi.org/10.5256/f1000research.13312.r25633

© 2017 Tamhankar P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parag Tamhankar
Genetic Research Center, National Institute For Research In Reproductive Health, Mumbai, Maharashtra, India

The queries raised previously have been adequately addressed. Hence, I recommend the paper to be accepted in the present form.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Medical genetics

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 09 January 2017

https://doi.org/10.5256/f1000research.9448.r15885

© 2017 Arora S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Shitij Arora ▶️
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10467, USA
A very interesting study. It highlights the increasing use of WES in diagnosing rare diseases. The authors confirm the findings of ES with Sangers and sequence both the parent and the proband. The manuscript needs editing and rearrangement of text. The paragraph on SME and AME needs/can probably be put together as the introduction. Minor grammar corrections.

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 October 2016

https://doi.org/10.5256/f1000research.9448.r16258

© 2016 Tamhankar P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parag Tamhankar
Genetic Research Center, National Institute For Research In Reproductive Health, Mumbai, Maharashtra, India

Please could you add an introduction about syndrome of apparent mineralocorticoid excess, for example;

Syndrome of apparent mineralocorticoid excess (MIM#218030) is a rare cause of juvenile hypertension occurring due to homozygous or compound heterozygous mutations in HSD11B2 gene (MIM*614232). The gene encodes an NAD+-dependent enzyme viz corticosteroid 11-β-dehydrogenase isozyme 2, which is expressed in aldosterone-selective epithelial tissues such as the kidney, colon, salivary and sweat glands. This enzyme is responsible for oxidizes the glucocorticoid cortisol to the inactive metabolite cortisone. This protective mechanism is necessary because cortisol circulates at 100-1000-fold higher concentrations than aldosterone, and binds with equal affinity to the mineralocorticoid receptor, thereby out-competing aldosterone in cells that do not produce HSD11B2. In patients with SME the enzyme deficiency allows mineralocorticoid receptors to be occupied by cortisol leading to hypertension.

I believe that more details on clinical features should be provided, such as:

- clinical presentation and history. Draw three generation pedigree.
- detailed anthropometry, examination findings of the patients. For eg. was there any low birth weight, short stature, polydipsia, polyuria?
- what were the baseline blood pressure levels in the patients when hypertension was detected?
- was fundus examination done to detect retinopathy?
- were the parents hypertensive?
- give the detailed serum electrolyte levels, detailed 2ECHO report. Give normal ranges of plasma renin, aldosterone levels.
- clinical photos if relevant
- or uploading ultrasound kidney scans

Mutation: Please give the nucleotide change, exon number of the mutation identified in the patients with the correct Ensembl transcript ID. Please specify as the mechanism of loss of function of the mutation in
patients with mutations at position p.335-339 is reduced protein stability due to rapid protein degradation at the proteasome, rather than reduced catalysis.

Grammar changes: I would begin the words aldosterone, amlodipine, metoprolol with lower case letters when in the midst of a sentence.

Typo: I think you should correct the following sentence - p.R337 loci of 11HSDB2 to- “The p.R337 residue of 11-β-dehydrogenase isozyme 2 enzyme is a recognised mutation site. The mutation p.R337C has been previously identified in a family from Iran with three affected children.”

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Author Response 30 Jul 2017**

Vinod Scaria, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, India

Please could you add an introduction about syndrome of apparent mineralocorticoid excess, for example;

Syndrome of apparent mineralocorticoid excess (MIM#218030) is a rare cause of juvenile hypertension occurring due to homozygous or compound heterozygous mutations in HSD11B2 gene (MIM*614232). The gene encodes an NAD+-dependent enzyme viz corticosteroid 11-β-dehydrogenase isozyme 2, which is expressed in aldosterone-selective epithelial tissues such as the kidney, colon, salivary and sweat glands. This enzyme is responsible for oxidizes the glucocorticoid cortisol to the inactive metabolite cortisone. This protective mechanism is necessary because cortisol circulates at 100-1000-fold higher concentrations than aldosterone, and binds with equal affinity to the mineralocorticoid receptor, thereby out-competing aldosterone in cells that do not produce HSD11B2. In patients with SME the enzyme deficiency allows mineralocorticoid receptors to be occupied by cortisol leading to hypertension.

We thank reviewers for the comments. Clarifications are as follows:

Clarification: The suggested changes in introduction section are made.

   Clarification 1: The suggestions have been incorporated. A two generation pedigree is provided. Information about the 3rd generation was not available.

2. detailed anthropometry, examination findings of the patients. For eg. was there any low birth weight, short stature, polydipsia, polyuria?
   Clarification 2: There was no h/o low birth weight, polydipsia or polyuria. All developmental milestones were normally attained in all siblings.

3. what were the baseline blood pressure levels in the patients when hypertension was detected?
   Clarification 3: Included in the case history section
4. was fundus examination done to detect retinopathy?
Clarification 4: No

5. were the parents hypertensive?
Clarification 5: No

6. give the detailed serum electrolyte levels, detailed 2ECHO report. Give normal ranges of plasma renin, aldosterone levels.
Clarification 6: Included in the case history section.

7. clinical photos if relevant
Clarification 7: None

8. or uploading ultrasound kidney scans
Clarification 8: The ultrasound scan is attached separately. It may not be of great quality, however shows medullary nephrocalcinosis (see this link).

9. Mutation: Please give the nucleotide change, exon number of the mutation identified in the patients with the correct Ensembl transcript ID. Please specify as the mechanism of loss of function of the mutation in patients with mutations at position p.335-339 is reduced protein stability due to rapid protein degradation at the proteasome, rather than reduced catalysis.
Clarification 9: Suggestions have been incorporated.

10. Grammar changes: I would begin the words aldosterone, amlodipine, metoprolol with lower case letters when in the midst of a sentence.
Clarification 10: Suggestions have been incorporated.

11. Typo: I think you should correct the following sentence - p.R337 loci of 11HSDB2 to- “The p.R337 residue of 11-β-dehydrogenase isozyme 2 enzyme is a recognised mutation site. The mutation p.R337C has been previously identified in a family from Iran with three affected children.”
Clarification 11: Suggestions have been incorporated.

**Competing Interests:** No competing interests were disclosed.
Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com